SG11201602783SA - Salt and crystal forms of plk-4 inhibitor - Google Patents

Salt and crystal forms of plk-4 inhibitor

Info

Publication number: SG11201602783SA
Authority: SG; Singapore
Prior art keywords: plk; inhibitor; salt; crystal forms; crystal
Prior art date: 2013-10-18

Application number

SG11201602783SA

Inventor

Peter Brent Sampson

Miklos Feher

Heinz W Pauls

Original Assignee

Univ Health Network

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-10-18

Filing date

2014-10-17

Publication date

2016-05-30

2014-10-17 Application filed by Univ Health Network filed Critical Univ Health Network

2016-05-30 Publication of SG11201602783SA publication Critical patent/SG11201602783SA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SG11201602783SA 2013-10-18 2014-10-17 Salt and crystal forms of plk-4 inhibitor SG11201602783SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361892564P	2013-10-18	2013-10-18
PCT/CA2014/051001 WO2015054793A1 (en)	2013-10-18	2014-10-17	Salt and crystal forms of plk-4 inhibitor

Publications (1)

Publication Number	Publication Date
SG11201602783SA true SG11201602783SA (en)	2016-05-30

Family

ID=52827507

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201602783SA SG11201602783SA (en)	2013-10-18	2014-10-17	Salt and crystal forms of plk-4 inhibitor

Country Status (26)

Country	Link
US (5)	US9884855B2 (en)
EP (1)	EP3057965B1 (en)
JP (1)	JP6492072B2 (en)
KR (3)	KR20220063299A (en)
CN (2)	CN105764899B (en)
AU (1)	AU2014336929B9 (en)
CA (1)	CA2926845C (en)
CY (1)	CY1121484T1 (en)
DK (1)	DK3057965T3 (en)
EA (1)	EA031569B1 (en)
ES (1)	ES2718603T3 (en)
HR (1)	HRP20190564T1 (en)
HU (1)	HUE043194T2 (en)
IL (1)	IL245038B (en)
LT (1)	LT3057965T (en)
ME (1)	ME03377B (en)
MX (1)	MX359069B (en)
NZ (1)	NZ718744A (en)
PL (1)	PL3057965T3 (en)
PT (1)	PT3057965T (en)
RS (1)	RS58413B1 (en)
SG (1)	SG11201602783SA (en)
SI (1)	SI3057965T1 (en)
TR (1)	TR201902875T4 (en)
TW (1)	TWI659952B (en)
WO (1)	WO2015054793A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010115279A1 (en)	2009-04-06	2010-10-14	University Health Network	Kinase inhibitors and method of treating cancer with same
PL2556071T3 (en)	2010-04-06	2017-02-28	University Health Network	Kinase inhibitors and their use in treating cancer
KR20220063299A (en)	2013-10-18	2022-05-17	유니버시티 헬스 네트워크	Salt and crystal forms of plk-4 inhibitor
EP3678669A4 (en) *	2017-09-08	2021-06-09	University Health Network	Combination therapies for inhibition of polo-like kinase 4
EP3959209A4 (en) *	2019-04-24	2022-12-28	University Health Network	Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate
EP4069246A4 (en) *	2019-12-06	2023-12-06	University Health Network	Treatment for acute myeloid leukemia or myelodysplastic syndrome
CA3217983A1 (en)	2021-05-11	2022-11-17	Chudi Ndubaku	Polo like kinase 4 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2483323A (en) *	1945-08-01	1949-09-27	Kay Fries Chemicals Inc	Method of preparing phenyl ethyl alcohol
US7205328B2 (en)	2002-10-21	2007-04-17	Irm Llc	Oxindoles with anti-HIV activity
DE102005005395A1 (en) *	2005-02-03	2006-08-10	Schering Aktiengesellschaft	New thiazolidinone compounds are polo-like kinase inhibitors, useful for treating e.g. cancer, autoimmune diseases, cardiovascular diseases, infectious diseases, nephrological diseases and viral diseases
GB0606234D0 (en) *	2006-03-29	2006-05-10	Pliva Istrazivanje I Razvoj D	Pharmaceutically acceptable salts and polymorphic forms
JP2010522078A (en) *	2007-03-23	2010-07-01	エージェンシーフォーサイエンス，テクノロジーアンドリサーチ	Palladium catalyst
JP5372939B2 (en) *	2007-09-25	2013-12-18	武田薬品工業株式会社	Polo-like kinase inhibitor
JP2011506494A (en) *	2007-12-21	2011-03-03	ユニバーシティ・ヘルス・ネットワーク	Indazolyl, benzimidazolyl, and benzotriazolyl substituted indolmon derivatives as kinase inhibitors useful in the treatment of cancer
WO2010115279A1 (en)	2009-04-06	2010-10-14	University Health Network	Kinase inhibitors and method of treating cancer with same
JP5801285B2 (en) *	2009-04-29	2015-10-28	ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ	CDK inhibitor salt
PL2556071T3 (en)	2010-04-06	2017-02-28	University Health Network	Kinase inhibitors and their use in treating cancer
WO2012000103A1 (en) *	2010-07-02	2012-01-05	University Health Network	Methods of targeting pten mutant diseases and compositions therefor
WO2012048411A1 (en) *	2010-10-13	2012-04-19	University Health Network	Plk-4 inhibitors and method of treating cancer with same
KR20130105675A (en) *	2010-11-25	2013-09-25	라티오팜 게엠베하	Novel salts and polymorphic forms of afatinib
CA2850394C (en) *	2011-10-12	2019-05-21	University Health Network	Indazole compounds as kinase inhibitors and method of treating cancer with same
KR20220063299A (en)	2013-10-18	2022-05-17	유니버시티 헬스 네트워크	Salt and crystal forms of plk-4 inhibitor
EP3057593B1 (en)	2013-10-18	2021-12-08	University Health Network	Treatment for pancreatic cancer

2014
- 2014-10-17 KR KR1020227015022A patent/KR20220063299A/en not_active Application Discontinuation
- 2014-10-17 NZ NZ718744A patent/NZ718744A/en unknown
- 2014-10-17 KR KR1020167012155A patent/KR20160070106A/en not_active Application Discontinuation
- 2014-10-17 MX MX2016004963A patent/MX359069B/en active IP Right Grant
- 2014-10-17 TW TW103135953A patent/TWI659952B/en active
- 2014-10-17 LT LTEP14854037.0T patent/LT3057965T/en unknown
- 2014-10-17 ES ES14854037T patent/ES2718603T3/en active Active
- 2014-10-17 KR KR1020217036751A patent/KR102395737B1/en active IP Right Grant
- 2014-10-17 SI SI201431110T patent/SI3057965T1/en unknown
- 2014-10-17 AU AU2014336929A patent/AU2014336929B9/en active Active
- 2014-10-17 CN CN201480064037.9A patent/CN105764899B/en active Active
- 2014-10-17 EA EA201690755A patent/EA031569B1/en not_active IP Right Cessation
- 2014-10-17 PT PT14854037T patent/PT3057965T/en unknown
- 2014-10-17 US US15/029,373 patent/US9884855B2/en active Active
- 2014-10-17 JP JP2016524077A patent/JP6492072B2/en active Active
- 2014-10-17 EP EP14854037.0A patent/EP3057965B1/en active Active
- 2014-10-17 WO PCT/CA2014/051001 patent/WO2015054793A1/en active Application Filing
- 2014-10-17 RS RS20190269A patent/RS58413B1/en unknown
- 2014-10-17 CA CA2926845A patent/CA2926845C/en active Active
- 2014-10-17 SG SG11201602783SA patent/SG11201602783SA/en unknown
- 2014-10-17 TR TR2019/02875T patent/TR201902875T4/en unknown
- 2014-10-17 ME MEP-2019-97A patent/ME03377B/en unknown
- 2014-10-17 HU HUE14854037A patent/HUE043194T2/en unknown
- 2014-10-17 PL PL14854037T patent/PL3057965T3/en unknown
- 2014-10-17 CN CN202110510808.4A patent/CN113248486A/en active Pending
- 2014-10-17 DK DK14854037.0T patent/DK3057965T3/en active
2016
- 2016-04-11 IL IL24503816A patent/IL245038B/en active IP Right Grant
2018
- 2018-02-01 US US15/886,104 patent/US10392374B2/en active Active
2019
- 2019-03-22 CY CY20191100336T patent/CY1121484T1/en unknown
- 2019-03-22 HR HRP20190564TT patent/HRP20190564T1/en unknown
- 2019-04-19 US US16/389,119 patent/US10472353B2/en active Active
- 2019-11-06 US US16/675,609 patent/US10919886B2/en active Active
2021
- 2021-02-10 US US17/172,511 patent/US11667627B2/en active Active

Also Published As

Publication number	Publication date
HUE043194T2 (en)	2019-08-28
IL245038B (en)	2019-11-28
KR102395737B1 (en)	2022-05-10
MX2016004963A (en)	2016-06-28
LT3057965T (en)	2019-03-12
WO2015054793A1 (en)	2015-04-23
AU2014336929B9 (en)	2019-03-21
JP6492072B2 (en)	2019-03-27
EP3057965A4 (en)	2017-05-24
CY1121484T1 (en)	2020-05-29
ES2718603T3 (en)	2019-07-03
KR20220063299A (en)	2022-05-17
AU2014336929B2 (en)	2018-11-22
US20200140428A1 (en)	2020-05-07
DK3057965T3 (en)	2019-04-01
ME03377B (en)	2020-01-20
PT3057965T (en)	2019-04-23
US9884855B2 (en)	2018-02-06
TW201609717A (en)	2016-03-16
KR20160070106A (en)	2016-06-17
CN113248486A (en)	2021-08-13
US20190248775A1 (en)	2019-08-15
US20180155335A1 (en)	2018-06-07
TR201902875T4 (en)	2019-03-21
IL245038A0 (en)	2016-05-31
TWI659952B (en)	2019-05-21
US20160264559A1 (en)	2016-09-15
RS58413B1 (en)	2019-04-30
EP3057965B1 (en)	2019-01-02
KR20210137251A (en)	2021-11-17
CN105764899B (en)	2021-06-01
CN105764899A (en)	2016-07-13
NZ718744A (en)	2021-07-30
EA201690755A1 (en)	2016-09-30
CA2926845C (en)	2023-06-13
US20210269428A1 (en)	2021-09-02
MX359069B (en)	2018-09-12
PL3057965T3 (en)	2019-08-30
US11667627B2 (en)	2023-06-06
SI3057965T1 (en)	2019-04-30
US10472353B2 (en)	2019-11-12
JP2016537326A (en)	2016-12-01
US10392374B2 (en)	2019-08-27
HRP20190564T1 (en)	2019-05-17
EA031569B1 (en)	2019-01-31
EP3057965A1 (en)	2016-08-24
CA2926845A1 (en)	2015-04-23
US10919886B2 (en)	2021-02-16

Publication	Publication Date	Title
HK1221224A1 (en)	2017-05-26	Crystal modifications of elobixibat
HK1213889A1 (en)	2016-07-15	Glutaminase inhibitors and method of use
EP2964651A4 (en)	2016-11-30	Bmp inhibitors and methods of use thereof
HRP20190564T1 (en)	2019-05-17	Salt and crystal forms of plk-4 inhibitor
EP2970311A4 (en)	2016-11-23	Bmp inhibitors and methods of use thereof
IL250391A0 (en)	2017-03-30	Crystal forms of glutaminase inhibitors
HRP20181291T1 (en)	2018-10-19	Heterobicycloaryl rorc2 inhibitors and methods of use thereof
PT3293176T (en)	2021-03-03	Crystal form of a pde4 inhibitor
SG11201507897SA (en)	2015-11-27	Salt of pyrazoloquinoline derivative, and crystal thereof
IL244268A0 (en)	2016-04-21	Heterocyclic compounds and methods of use
PL3019477T3 (en)	2021-11-22	Heterocyclic compounds and methods of their use
HK1222339A1 (en)	2017-06-30	Inhibitors of metallo-ss-lactamase-enzymes --
IL240763A0 (en)	2015-10-29	Halogenopyrazoles as inhibitors of therombin
GB201312311D0 (en)	2013-08-21	Uses of enzyme inhibitors